文献速递血液净化与透析肾血管病与高血压

中心血透患者家庭血压与透析前血压治疗目标的随机对照预试验

Treating Home Versus Predialysis Blood Pressure Among In-Center Hemodialysis Patients: A Pilot Randomized Trial.
PubMed 文献 · Am J Kidney Dis · 2020-08-13

该4个月平行随机对照预试验纳入50例维持性血透患者,比较以家庭收缩压100-<140 mmHg与透析前收缩压100-<140 mmHg为治疗目标的可行性。结果显示家庭血压组依从性达97.4%,高/低透析前血压读数频率未增加,但疲劳发生率较高(32% vs 16%)。

要点

  • 以家庭收缩压100-<140 mmHg为目标治疗血透患者可行且依从性高。
  • 家庭血压组未增加透析前高或低血压读数频率。
  • 家庭血压组疲劳发生率高于透析前血压组(32% vs 16%)。

核心结论

  • 预试验表明在血透患者中以家庭血压为目标进行治疗可行且依从性高。

研究设计与样本

  • 4个月平行随机对照预试验,纳入50例维持性血透患者,按1:1区组随机分组并按中心分层。

主要发现

  • 70例受邀患者中50例(71%)同意参与,除1例接受肾移植外均完成研究。
  • 家庭血压组获取/报告家庭血压的依从性为97.4%且4个月内保持稳定。
  • 家庭血压组与透析前血压组透析前高收缩压(>200 mmHg)读数频率分别为0.2%与0%,低收缩压(<90 mmHg)读数频率分别为1.8%与1.2%。
  • 家庭血压组疲劳发生率高于透析前血压组(32% vs 16%)。

关键数值与推荐

  • 家庭血压组目标为家庭收缩压100-<140 mmHg,透析前血压组目标为透析前收缩压100-<140 mmHg。
  • 每2周评估家庭和透析前收缩压,调整干体重和降压药物以达到目标收缩压。

临床怎么用

  • 血透患者可考虑以家庭收缩压100-<140 mmHg作为治疗目标,但需关注疲劳等不良反应。

局限性

  • 样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Observational studies have reported a U-shaped association between blood pressure (BP) before a hemodialysis session and death. In contrast, because a linear association between out-of-dialysis-unit BP and death has been reported, home BP may be a better target for treatment. To test the feasibility of this approach, we conducted a pilot trial of treating home versus predialysis BP in hemodialysis patients. STUDY DESIGN: A 4-month, parallel, randomized, controlled trial. SETTINGS & PARTICIPANTS: 50 prevalent hemodialysis patients in San Francisco and Seattle. Participants were randomly assigned using 1:1 block randomization, stratified by site. INTERVENTIONS: To target home systolic BP (SBP) of 100-<140 mm Hg versus predialysis SBP of 100-<140mm Hg. Home and predialysis SBPs were ascertained every 2 weeks. Dry weight and BP medications were adjusted to reach the target SBP. OUTCOMES: Primary outcomes were feasibility, adherence, safety. and tolerability. RESULTS: 50 of 70 (71%) patients who were approached agreed to participate. All enrollees completed the study except for 1 who received a kidney transplant. In the home BP treatment group, adherence to obtaining/reporting home BP was 97.4% (and consistent over the 4 months). There was no increased frequency of high (defined as SBP>200mm Hg; 0.2% vs 0%) or low (defined as<90mm Hg; 1.8% vs 1.2%) predialysis BP readings in the home versus predialysis treatment arms, respectively. However, participants in the home BP arm had higher frequency of fatigue (32% vs 16%). LIMITATIONS: Small sample size. CONCLUSIONS: This pilot trial demonstrates feasibility and high adherence to home BP measurement and treatment in hemodialysis patients. Larger trials to test the long-term feasibility, efficacy, and safety of home BP treatment in hemodialysis patients should be conducted. FUNDERS: National Institutes of Health, Satellite Healthcare, and Northwest Kidney Centers. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT03459807.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Bansal N, Glidden DV, Mehrotra R, et al. Treating Home Versus Predialysis Blood Pressure Among In-Center Hemodialysis Patients: A Pilot Randomized Trial. Am J Kidney Dis. 2020. PMID: 32800842. doi:10.1053/j.ajkd.2020.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。